BCAX Stock — Bicara Therapeutics Inc.: Metrics

Market overview

2 metrics

Share price

$23.56

Market cap

$1.56B

Price action

19 metrics

Price change (1W)

-4.7%

Price change (30D)

-9.0%

Price change (3M)

+19.2%

Price change (6M)

+30.7%

Price change (YTD)

+39.2%

Price change (1Y)

+96.1%

Trailing year

Price change (5Y)

—

52-week high

$30.40

52-week low

$10.44

Change from 52-week high

-23.0%

Change from 52-week low

+124.3%

Annualized volatility

61.0%

Beta

1.0

RSI (14D)

41.4

Price vs SMA 50

-11.9%

Price vs SMA 200

+12.2%

Avg volume (3M)

719,450

Relative volume

0.6

Average dollar volume

$18.59M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

66.17M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

3.3

reciprocal yield 30.6%

FCF yield

-8.8%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-12.1%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-08-11

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$201.99M

Net income (TTM)

−$185.36M

Trailing 12 months

Diluted EPS (TTM)

$-3.09

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-232.31

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+24.5%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-39.5%

Return on assets

-36.2%

Debt / equity

—

Current ratio

11.6

EBITDA (TTM)

—

Free cash flow (TTM)

−$135.25M

Quick ratio

11.6

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$497.26M

Latest balance sheet

Cash & equivalents

$96.60M

Total assets

$512.24M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$134.85M

Capital expenditures (TTM)

$400,000

R&D (TTM)

$112.00M

SG&A (TTM)

—

Stock compensation (TTM)

$22.16M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

176

13F filer change QoQ

+29

Institutional ownership

105.9%

Short interest

3 metrics

Short interest

15.8%

Latest settlement · 13.3 days to cover

Days to cover

13.3d

Short-squeeze score

74 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$3.08M

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

BCAX · Bicara Therapeutics Inc.

BCAX metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search